The United States of America, as represented by the Secretary, Department of Health and Human Serv Patent applications |
Patent application number | Title | Published |
20160136256 | POLYSACCHARIDE-PROTEIN CONJUGATE VACCINES - Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency, such that a simplified purification process can be employed to separate the conjugate product from the unconjugated protein and polysaccharide and other small molecule by-products. | 05-19-2016 |
20160129138 | OCTAPOD IRON OXIDE NANOPARTICLES AS HIGH PERFORMANCE T2 CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING - Disclosed are nanoparticles comprising octapod iron oxide having eight trigonal bipyramidal arms and a method of preparing the same. The nanoparticles are prepared by heating a mixture of a ferric carboxylate, a carboxylic acid, a chloride salt, water, and a non-polar solvent, to a temperature above about 300° C. Also disclosed is a method of magnetic resonance imaging a tissue in a mammal, comprising use of the aforesaid nanoparticles. | 05-12-2016 |
20160114026 | PAN-LYSSAVIRUS VACCINES AGAINST RABIES - Described herein are recombinant rabies viruses encoding rabies virus glycoprotein and at least one heterologous glycoprotein from another lyssavirus, such as Mokola virus, Lagos bat virus and/or West Caucasian bat virus. In particular embodiments, the recombinant rabies virus includes two or three heterologous lyssavirus glycoproteins. The disclosed recombinant rabies viruses can be used as pan-lyssavirus vaccines to provide protection against lyssaviruses that cause rabies. | 04-28-2016 |
20160108097 | MONOMERIC GRIFFITHSIN TANDEMERS - The invention provides a construct containing two or more monomeric griffithsin molecules, optionally joined by a linker, as well as conjugate comprising the construct, a nucleic acid encoding the construct or conjugate, vectors, and cells. A nucleic acid encoding the polypeptide or fusion protein, as well as compositions or cells comprising the polypeptide, fusion protein, or nucleic acid also are provided. | 04-21-2016 |
20160102369 | DETECTION OF ECHINOCANDIN-RESISTANT CANDIDA GLABRATA - Probes and primers are disclosed for detecting a | 04-14-2016 |
20160081798 | TENSIONING DEVICE AND METHODS FOR USE - A tensioning device is provided comprising a locking device. The locking device comprises a locking enclosure comprising a groove and a locking pin comprising teeth. The tensioning device further comprises a suture comprising first and second portions. The first and second portions of the suture and the locking pin are positioned within the groove of the locking enclosure and the locking pin is movable within the groove between a first, outer position in which the teeth are disengaged from the suture so that the locking device is movable along the first and second portions of the suture and a second, inner position in which the teeth are engaged with the suture so that the locking device is not movable along the suture. Methods for treating mitral valve regurgitation are also provided. | 03-24-2016 |
20160075786 | USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND A4B7 INTEGRIN - Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and α4 integrin, such as a α4β1 or α4β7 integrin antagonist, thereby treating the HIV infection. In several examples, the α4 integrin antagonist is a monoclonal antibody that specifically binds to a α4, β1 or β7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and α4 integrin, such as a α4β1 or α4β7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV. | 03-17-2016 |
20160046677 | PSEUDOMONAS EXOTOXIN A WITH LESS IMMUNOGENIC B CELL EPITOPES - The invention provides a | 02-18-2016 |
20160031957 | INHIBITORS OF THE LINEAR UBIQUITIN CHAIN ASSEMBLY COMPLEX (LUBAC) AND RELATED METHODS - The invention relates to peptide inhibitors of linear ubiquitin chain assembly complex (LUBAC) and to methods of treating diseases including activated B-cell like diffuse large B cell lymphboma (ABC DLBCL) and autoimmune or inflammatory disorders. | 02-04-2016 |
20160025717 | HYPOSIALYLATION DISORDERS - Methods are disclosed for diagnosing a hyposialylation disorder. Methods are also disclosed for determining the effectiveness of a therapeutic agent for treatment of a hyposialylation disorder in a subject. These methods include measuring an amount of monosialylated Thomsen-Friedenreich (ST) antigen and measuring an amount of non-sialylated Thomsen-Friedenreich antigen (T) in a biological sample, such as a serum or plasma sample from the subject, and determining the ratio of T to ST. | 01-28-2016 |
20160000794 | METHODS FOR THE DIAGNOSIS AND TREATMENT OF SJOGREN'S SYNDROME - The finding that patients with Sjögren's syndrome exhibit a statistically significant increase in expression of BMP6 in the salivary gland, relative to healthy control subjects, is described. Also described is the finding that overexpression of BMP6 in the salivary glands of mice results in an increase in electrical potential across the salivary gland. Methods of diagnosing a subject as having Sjögren's syndrome, or at risk for developing Sjögren's syndrome, by measuring the level of BMP6 expression in a salivary gland of a subject, measuring electrical potential in a salivary gland of a subject, or both, are described. Methods of treating a subject with Sjögren's syndrome, or methods of increasing salivary flow in a subject, by administering an agent that inhibits BMP6 expression or activity are also described. The use of XIST and MECP2 as diagnostic and therapeutic targets for male Sjögren's syndrome patients is further described. | 01-07-2016 |
20150374661 | BIOLOGICALLY ACTIVE MACROLIDES, COMPOSITIONS, AND USES THEREOF - The present invention provides a compound of the formula (I) or (II), wherein R | 12-31-2015 |
20150359784 | THIO COMPOUNDS - A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: | 12-17-2015 |
20150290229 | N-ACETYL MANNOSAMMINE AS A THERAPEUTIC AGENT - The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine. | 10-15-2015 |
20150273083 | METHODS FOR THE DIAGNOSIS AND TREATMENT OF SJOGREN'S SYNDROME - Described herein is the finding that patients with Sjögren's syndrome exhibit a statistically significant increase in expression of BMP6 in the salivary gland, relative to healthy control subjects. Also described herein is the finding that overexpression of BMP6 in the salivary glands of mice results in an increase in electrical potential across the salivary gland. Thus, provided herein are methods of diagnosing a subject as having Sjögren's syndrome, or at risk for developing Sjögren's syndrome, by measuring the level of BMP6 expression in a salivary gland of a subject, measuring electrical potential in a salivary gland of a subject, or both. Also provided herein are methods of treating a subject with Sjögren's syndrome by administering an agent that inhibits expression of BMP6 expression or activity. Also described herein is the use of XIST and MECP2 as diagnostic and therapeutic targets for male Sjögren's syndrome patients. | 10-01-2015 |
20150272972 | INHIBITION OF HIV INFECTION THROUGH CHEMOPROPHYALXIS - A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host. A process for controlling retrovirus transmission within a population includes the administration to a subpopulation at high risk for contracting an immunodeficiency retroviral infection the detailed combination prior to sexual exposure to a source of immunodeficiency retrovirus so as to preclude the immunodeficiency retrovirus from becoming self-replicating in a member of the subpopulation. | 10-01-2015 |
20150232475 | NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS - The invention provides novel nicotinic acetylcholine receptor agonists, for example, phantasmidine and derivatives thereof, for example a compound of formula I. Also disclosed are methods of treating disorders responsive to nicotinic acetylcholine receptor agonists such as Alzheimer's disease, schizophrenia, Myasthenia Gravis, Tourette's syndrome, Parkinson's disease, epilepsy, pain, and cognitive dysfunction by treatment with the nicotinic acetylcholine receptor agonists. | 08-20-2015 |
20150218525 | HUMAN EBOLA VIRUS SPECIES AND COMPOSITIONS AND METHODS THEREOF - Compositions and methods including and related to the Ebola | 08-06-2015 |
20150152144 | SALMONELLA TYPHI TY21A EXPRESSING YERSINIA PESTIS F1-V FUSION PROTEIN AND USES THEREOF - Described herein is the generation of a plasmid construct for expression of a | 06-04-2015 |
20150132297 | SURVIVAL PREDICTOR FOR DIFFUSE LARGE B CELL LYMPHOMA - The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients. | 05-14-2015 |
20150125459 | APELIN PEPTIDES, ANTIBODIES THERETO, AND METHODS OF USE - The present disclosure concerns the use of biologically active apelin peptides and compositions that are processed from larger precursor proteins and further post-translationally modified to influence cell growth. Particular methods are useful for promoting cell growth, while others are particularly useful for inhibiting cell growth. | 05-07-2015 |
20150093412 | USE OF SACCHARIDES CROSS-REACTIVE WITH BACILLUS ANTHRACIS SPORE GLYCOPROTEIN AS A VACCINE AGAINST ANTHRAX - Provided are immunogenic compositions and methods for eliciting an immune response against | 04-02-2015 |
20150091573 | HYPERPOLARIZED MEDIA TRANSPORT VESSEL - A system and method for transporting a hyperpolarized substance is disclosed. A transport vessel for transporting such a hyperpolarized substance includes a vessel housing, a chamber formed within the vessel housing that is configured to receive a container holding a hyperpolarized substance, and an electromagnet configured to generate a magnetic containment field about the chamber when a current is supplied thereto, the magnetic containment field comprising a homogeneous magnetic field. The transport vessel also includes a non-magnetic power source to supply the current to the electromagnet and a control circuit configured to selectively interrupt the supply of current to the electromagnet so as to control generation of the magnetic containment field, with the transport vessel being magnetically inert when the supply of current to the electromagnet is interrupted by the control circuit. | 04-02-2015 |
20140342407 | NEUTRALIZING GP41 ANTIBODIES AND THEIR USE - Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection. | 11-20-2014 |
20140341909 | CONJUGATION OF BIOMOLECULES USING DIELS-ALDER CYCLOADDITION - A method is provided for covalently linking carbohydrates, proteins, nucleic acids, and other biomolecules under neutral conditions, using a Diels-Alder cycloaddition reaction. In an example, activated carbon-carbon double bonds were attached to free amino sites of a carrier protein, and a conjugated diene was attached to a carbohydrate hapten. Spontaneous coupling of the carbohydrate and the protein components under very mild conditions provided glycoconjugates containing up to 37 carbohydrate hapten units per carrier protein molecule. The method is also applicable to the immobilization of biomolecules on gel or solid supports. The conjugated products are useful as immunogens and as analytical and diagnostic reagents. | 11-20-2014 |
20140341876 | METHOD FOR THE TREATMENT OF PULMONARY DISEASE AND METHOD OF PRODUCING PROTEINS OF USE THEREIN - Methods of treating a subject with pulmonary disease by administering a therapeutically effective amount of a defensin polypeptide including at least one arginine residue susceptible to ADP-ribosylation and nicotinamide adenine dinucleotide (NAD), are described. The polypeptide and/or NAD can be administered via inhalation. Also disclosed is a pharmaceutical composition including at least one defensin polypeptide and NAD. In vitro methods of producing a polypeptide with altered activity, including contacting the polypeptide with NAD and an arginine-specific mono-ADP-ribosyltransferase to produce a polypeptide including at least one ADP-ribosylated arginine residue, incubating the ADP-ribosylated polypeptide under conditions sufficient for conversion of at least one ADP-ribosylated arginine residue to ornithine, and isolating the ornithine-containing polypeptide, are also described. Methods of treating a subject with pulmonary disease by administering a therapeutically effective amount of a modified defensin polypeptide including at least one ornithine residue in place of an arginine residue are also disclosed. | 11-20-2014 |
20140341812 | BETA-AMYLOID PET IMAGING AGENTS - Novel derivatives of imidazopyridinylbenzeneamines and novel derivatives of benzothiazolylbenzeneamines are disclosed that offer improved behavior when used as imaging agents for positron emission tomography of beta-amyloids. Also disclosed is a palladium-catalyzed reaction scheme under microwave conditions for aryl thioethers in general that provides a high ratio of substitution relative to reduction and can be used for the imidazopyridinylbenzeneamine derivatives as well as other compounds of related structure. | 11-20-2014 |
20140328901 | METHODS FOR USING INTERFERON GAMMA TO ABSORB FLUID FROM THE SUBRETINAL SPACE - Particular aspects of the invention provide methods for decreasing the amount of fluid present in the subretinal space of the eye by administering interferon gamma to the basolateral side of the retinal pigment epithelium. Adverse ocular conditions associated with the accumulation of fluid in the subretinal space can be treated by administering an amount of interferon gamma to the basolateral side of the retinal pigment epithelium effective to remove excess fluid from the subretinal space. | 11-06-2014 |
20140322163 | NEUTRALIZING ANTIBODIES TO HIV-1 AND THEIR USE - Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed. | 10-30-2014 |
20140314841 | Use of Cysteamine and Derivatives Thereof to Suppress Tumor Metastases - The present disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or derivatives thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein. | 10-23-2014 |
20140302518 | DETECTION OF INFECTIOUS PRION PROTEIN BY SEEDED CONVERSION OF RECOMBINANT PRION PROTEIN - The present disclosure relates to methods and compositions for the detection of infectious proteins or prions in samples, including the diagnosis of prion related diseases. One embodiment is an ultrasensitive method for detecting PrP-res (PrP | 10-09-2014 |
20140301944 | LOW MOLECULAR WEIGHT THYROID STIMULATING HORMONE RECEPTOR (TSHR) AGONISTS - Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder. | 10-09-2014 |
20140296249 | 4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE | 10-02-2014 |
20140249181 | TROPOLONE COMPOUNDS FOR TREATING OR PREVENTING RETROVIRAL INFECTION - Disclosed are compounds that inhibit RNase H activity of retroviruses, for example, a compound of formula (I) wherein R | 09-04-2014 |
20140249145 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS - Substituted pyrazolopyrimidines and dihydropyrazolopyrimidines and related compounds, their methods of manufacture, compositions containing these compounds, and methods of use of these compounds in treating lysosomal storage disorders such as Gaucher disease are described herein. The compounds are of general Formula (I) | 09-04-2014 |
20140243284 | BIOLOGICALLY ACTIVE MACROLIDES, COMPOSITIONS, AND USES THEREOF - The present invention provides a compound of the formula (I) or (II), wherein R | 08-28-2014 |
20140234969 | METHODS FOR ENHANCING GENOME STABILITY AND TELOMERE ELONGATION IN EMBRYONIC STEM CELLS - The disclosure provides methods for increasing genome stability of an embryonic stem (ES) cell or induced pluripotent stem (iPS) cell, increasing telomere length in an ES or iPS cell, or both, for example by contacting an ES or iPS cell with an agent that increases expression of Zscan4 in the cell. Methods for increasing genome stability or increasing telomere length in a population of ES or iPS cells are provided, for example by selecting Zscan4 | 08-21-2014 |
20140234353 | METHODS OF OBTAINING ANTIGEN-SPECIFIC T CELL POPULATIONS - The invention provides a method of obtaining a population of antigen-specific T cells from peripheral blood of a host. An embodiment of the method of the invention comprises (i) dividing PBMCs from peripheral blood of a host into more than one sub-population; (ii) contacting the PBMCs with an antigen and IL-2; (iii) obtaining a sample of PBMCs from each sub-population; (iv) identifying an antigen-reactive sub-population by determining by high throughput quantitative PCR the expression of a factor produced by the PBMCs of each sample; (v) dividing the antigen-reactive sub-population into microcultures; (vi) identifying the antigen-reactive microculture; and (vii) expanding the microculture, thereby obtaining a population of T cells specific for the antigen. The invention also provides a population of T cells obtained by the inventive method, a pharmaceutical composition comprising the same, and a method of treating a disease in a host using the pharmaceutical composition. Related isolating and screening methods are further provided. | 08-21-2014 |
20140213529 | PSEUDOMONAS EXOTOXIN A WITH LESS IMMUNOGENIC B CELL EPITOPES - The invention provides a | 07-31-2014 |
20140213479 | METHODS AND COMPOSITIONS FOR DETECTING IMMUNE RESPONSES - Methods and compositions for detecting immune responses and antigen-specific cells are described herein. | 07-31-2014 |
20140212967 | MICROFABRICATED POLYMERIC VESSEL MIMETICS - The present disclosure is directed to embodiments of microstructured membranes, methods of fabricating microstructured membranes, bioreactors housing microstructured membranes, and methods of using bioreactors and microstructured membranes. In some embodiments, the present disclosure allows culturing of cellular tissues in an environment which more accurately resembles a native environment. In some more specific embodiments, the present disclosure allows culturing of tumor cells on a membrane having a microfabricated pattern which mimics a native vasculature system. | 07-31-2014 |
20140206758 | EXPRESSION OF IL-12 FAMILY HETERODIMERS - The present invention provides methods of improving the levels and stability of expression of interleukin-12 family cytokine polypeptides by expressing the alpha and beta subunits of the polypeptides at their determined relative molar ratios that increase the levels and stability of expression of the heterodimer, e.g., in comparison to heterodimer expressed at an equimolar ratio. | 07-24-2014 |
20140206620 | T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE - The invention provides T cell receptors (TCRs) having antigenic specificity for a cancer antigen, e.g., tyrosinase. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials. | 07-24-2014 |
20140200160 | MOLECULAR-BASED METHOD OF CANCER DIAGNOSIS AND PROGNOSIS - A gene profiling signature for diagnosis and prognosis of cancer patients is disclosed herein. In one embodiment, the gene signature includes 32 or 79 cancer survival factor-associated genes. Thus, provided herein is a method of determining the prognosis of a subject with a tumor by detecting expression of five of more cancer survival factor-associated genes in a tumor sample and comparing expression of the five or more cancer survival factor-associated genes in the tumor sample to a control. In some examples, an increase in expression of ABCF1, CORO1C, DPP3, PREB, UBE3A, and PTDSS1 in a tumor sample compared to a control sample indicates poor prognosis. Further provided are arrays including probes or antibodies specific for a plurality of cancer survival factor-associated genes or proteins. | 07-17-2014 |
20140141431 | USE OF ERBB4 AS A PROGNOSTIC AND THERAPEUTIC MARKER FOR MELANOMA - Members of the protein tyrosine kinase (PTK) family are highly mutated in patients with melanoma. Described herein are novel somatic mutations in the ERBB4 gene that result in increased kinase activity, transformation ability and anchorage-independent growth. These ERBB4 mutations contribute to the tumorogenicity of melanoma. Provided is a method of predicting the prognosis of a patient with melanoma by detecting the presence or absence of a mutation in the ERBB4 gene. In some examples, the ERBB4 mutation is selected from G949A, G1354A, G1624A, C1630T, G1687A, G2506A and G2614A (numbering based on SEQ ID NO: 1). Also provided are methods of selecting a patient as a candidate for treatment with an ERBB4 and/or PI3K/AKT pathway inhibitor, and a method of identifying a therapeutic agent for the treatment of a subject diagnosed with melanoma. Oligonucleotides that specifically hybridize with an ERBB4 nucleic acid molecule comprising a novel mutation are also provided. | 05-22-2014 |
20140127246 | SPANX-B POLYPEPTIDES AND THEIR USE - It is disclosed herein that SPANX-B is uniquely expressed in a number of human tumors and that SPANX-B is an immunogenic antigen that is recognized by human T cells inducing helper CD4 | 05-08-2014 |
20140107089 | STRUCTURAL MODIFICATION OF 19-NORPROGESTERONE I: 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS NEW ANTIPROGESTATIONAL AGENTS - Disclosed are compounds having the general formula: | 04-17-2014 |
20140100163 | NON-PEPTIDE AGONISTS AND ANTAGONISTS OF ADRENOMEDULLIN AND GASTRIN RELEASING PEPTIDE - This invention relates, e.g., to methods for inhibiting or stimulating an activity of an adrenomedullin (AM) or gastrin releasing peptide (GRP) peptide hormone, comprising contacting the peptide with a small molecule, non-peptide, modulatory agent of the invention. Complexes of these modulatory agents with other components, such as the peptides or blocking antibodies specific for the peptides, are also described, as are pharmaceutical compositions comprising the modulatory agents, and methods for using the modulatory agents to diagnose or treat patients. | 04-10-2014 |
20140037581 | METHODS TO DIAGNOSE AND IMMUNIZE AGAINST THE VIRUS CAUSING HUMAN MERKEL CELL CARCINOMA - The present invention provides isolated or substantially purified polypeptides, nucleic acids, and virus-like particles (VLPs) derived from a Merkel cell carcinoma virus (MCV), which is a newly-discovered virus. The invention further provides monoclonal antibody molecules that bind to MCV polypeptides. The invention further provides diagnostic, prophylactic, and therapeutic methods relating to the identification, prevention, and treatment of MCV-related diseases. | 02-06-2014 |
20140023679 | LIVE ATTENUATED VIRUS VACCINES FOR LA CROSSE VIRUS AND OTHER BUNYAVIRIDAE - The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae. | 01-23-2014 |
20130345391 | Composite Probes and Use Thereof in Super Resolution Methods - Composite probes for super resolution optical techniques using super resolution via transiently activated quenchers (STAQ) include a donor moiety and an acceptor moiety joined by a linker, wherein the acceptor moiety, when excited by incident radiation, is excited to a state which, for example, absorbs in the donor emission region, such that the acceptor moiety in its excited state quenches at least a portion of the donor moiety emission. Other transiently activated quenching mechanisms and moieties could accomplish the same task by reducing donor population. Also disclosed are methods for irradiating a selected region of a target material including the composite probe, wherein the composite probe enables improved resolution by point spread function modification and/or nanoscale chemical reactions. | 12-26-2013 |
20130331460 | CHRYSOPHAENTIN ANALOGS THAT INHIBIT FTSZ PROTEIN - Embodiments of antimicrobial chrysophaentin compounds, pharmaceutical compositions including the chrysophaentin compounds, methods for using the chrysophaentin compounds, and methods for synthesizing the chrysophaentin compounds are disclosed. Certain embodiments of the chrysophaentin compounds inhibit FtsZ protein, thereby inhibiting the growth of clinically relevant bacteria, including drug-resistant strains. | 12-12-2013 |
20130316957 | SMOOTHENED POLYPEPTIDES AND METHODS OF USE - Disclosed is an isolated or purified polypeptide or peptidomimetic comprising an amino acid sequence of a portion of a Smoothened (SMO) protein, wherein the portion comprises an amino acid sequence of any of the intracellular loops of the SMO protein, a functional fragment thereof, or a functional variant of either the portion or the functional fragment, wherein the functional fragment comprises at least 7 contiguous amino acids of the intracellular loops, and wherein the functional fragment or functional variant inhibits proliferation of a diseased cell, or a fatty acid derivative thereof. Related conjugates, nucleic acids, recombinant expression vectors, host cells, and pharmaceutical compositions are further provided. Methods of inhibiting proliferation of a diseased cell, treating or preventing cancer, treating a neoplasm or psoriasis, and inhibiting the expression of genes involved in the Hedgehog signaling pathway, thereby inhibiting the Hedgehog signaling pathway, are furthermore provided by the invention. | 11-28-2013 |
20130316947 | THERAPEUTIC USE OF SCGB3A2 - The present disclosure is generally related to methods of using the secretory protein SCGB3A2 for promoting lung development and treating lung disease. Some embodiments are, for example, methods for treating and inhibiting the development of neonatal respiratory distress. Other embodiments are methods of promoting lung development in damaged or diseased lungs. Also disclosed are methods for inhibiting lung damage due to anti-cancer agents. | 11-28-2013 |
20130274591 | SINGLE CHANNEL MRI GUIDEWIRE - The present application discloses a guidewire for magnetic resonance imaging with a single channel design to reduce complexity and to provide conspicuous tip visibility under MRI. In one embodiment, a guidewire body includes an antenna formed from a rod and a helical coil coupled together. The helical coil can have multiple windings without any gaps between the windings. The rod passes through the windings of the helical coil and is coupled to the helical coil using a conductive joint positioned at an end of the rod and at an end of the helical coil. Insulation can be positioned between the rod and the windings of the helical coil. The configuration allows visibility of the antenna along the length of a rod, except where it enters the windings of the coil. Thus, the tip visibility is enhanced as being separated from the rod. | 10-17-2013 |
20130274203 | ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE - The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for synovial sarcoma X Breakpoint (SSX)-2. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention. | 10-17-2013 |
20130273111 | DIAGNOSTIC ASSAYS AND METHODS OF USE FOR DETECTION OF FILARIAL INFECTION - The polynucleotide encoding the antigen Wb123 from the filarial nematode | 10-17-2013 |
20130243769 | INDUCED INTERNALIZATION OF SURFACE RECEPTORS - Disclosed is a hetero-bifunctional ligand for use in inducing internalization of a target receptor. The hetero-bifunctional ligand includes a target receptor-binding agent that specifically binds the target receptor linked to an internalizing receptor-binding agent that specifically binds to an internalizing receptor, where the two binding agents are non-identical. Also disclosed is a method of inducing the internalization of a target receptor on a cell. The method includes contacting a cell with a hetero-bifunctional ligand, where binding of the hetero-bifunctional ligand induces internalization of a target receptor of the cell. Also disclosed is a method of treating a disease or condition associated with a target receptor using the disclosed hetero-bifunctional ligand and pharmaceutical compositions including a hetero-bifunctional ligand. | 09-19-2013 |
20130186173 | DEVICE FOR SIMULATING EXPLOSIVE BLAST AND IMAGING BIOLOGICAL SPECIMEN - A device and method for simulating a blast shock wave of the type produced by explosive devices such as bombs. A pneumatic charge releases a blast shock wave along a conduit which terminates in a first outlet that communicates with the atmosphere and a second outlet that is sealed to a specimen chamber. The first outlet has a quick release valve that prevents venting of the pneumatic charge to the atmosphere until the pressure at the valve reaches a predetermined level that opens the valve. The pneumatic charge therefore initially flows through the second outlet to direct the blast into the specimen chamber, until subsequent opening of the quick release valve redirects the gas flow out of the first outlet and rapidly reduces pressure in the chamber. The blast wave closely simulates the Friedlander curve, and its effects are viewed during instead of only after the blast is completed. | 07-25-2013 |
20130143966 | METHODS OF TREATMENT USING STERCULIC ACID - The use of sterculic acid, and the pharmaceutically acceptable salt forms thereof, described for the treatment of inflammation, in particular, 7-ketocholesterol induced inflammation, 7-keto-cholesterol toxicity, and unregulated angiogenesis. | 06-06-2013 |
20130109619 | PEPTIDE-BASED INHIBITOR OF INTERLEUKIN-10 OR INTERFERON-GAMMA SIGNALING | 05-02-2013 |
20130039886 | BETA-MANNOSYLCERAMIDE AND STIMULATION OF NKT CELL ANTI-TUMOR IMMUNITY - β-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of α-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising β-mannosylceramide, as well as methods of treatment of tumors are also provided. | 02-14-2013 |
20120320458 | AZICON BEAM POLARIZATION DEVICES - Polarizers and polarizing beam splitter include one or more pairs of axicons that are configured to separate an input beam into a radially polarized component and a tangentially (or azimuthally) polarized component. A second axicon pair can be provided to recombine the tangentially polarized component so as to provide a more uniform beam intensity. The radially polarized component can be reflected or otherwise directed so that one or both the radial and tangential components are available for use. | 12-20-2012 |
20120142624 | AKT PHOSPHORYLATION AT SER473 AS AN INDICATOR FOR TAXANE-BASED CHEMOTHERAPY - Methods for determining whether a cancer patient is likely to benefit from treatment with a taxane compound based on Akt-Ser473 phosphorylation status are provided, together with kits for determining Akt-Ser473 phosphorylation status and methods for improving treatment of a cancer patient that include obtaining a determination of the Akt-Ser473 phosphorylation status of the cancer. | 06-07-2012 |
20120068699 | PHANTOM FOR DIFFUSION MRI IMAGING - A phantom calibration body ( | 03-22-2012 |
20110282060 | NITRIC OXIDE-RELEASING DIAZENIUMDIOLATED COMPOUNDS - The invention described herein provides for novel nitric oxide-releasing polymers that comprise at least two adjacent units derived from acrylonitrile monomer units and containing at least one carbon-bound diazeniumdiolate. The diazeniumdiolated acrylonitrile-derived polymers can be used in medical devices therapeutically. Accordingly, the invention also provides a method of treating a biological disorder and a method of promoting angiogenesis that includes administering a medical device comprising a nitric oxide-releasing polymer comprising at least two adjacent units of acrylonitrile before exposure to nitric oxide and at least one nitric oxide releasing N | 11-17-2011 |
20110195064 | SURVIVAL PREDICTOR FOR DIFFUSE LARGE B CELL LYMPHOMA - The invention provides methods and materials related to a gene expression-based survival predictor for diffuse large B cell lymphoma (DLBCL) patients. | 08-11-2011 |
20110052530 | ADOPTIVE CELL THERAPY WITH YOUNG T CELLS - The invention provides a method of promoting regression of a cancer in a mammal comprising (i) culturing autologous T cells; (ii) expanding the cultured T cells; (iii) administering to the mammal nonmyeloablative lymphodepleting chemotherapy; and (iv) after administering nonmyeloablative lymphodepleting chemotherapy, administering to the mammal the expanded T cells, wherein the T cells administered to the mammal are about 19 to about 35 days old and have not been screened for specific tumor reactivity, whereupon the regression of the cancer in the mammal is promoted. | 03-03-2011 |
20090162390 | Molecular Scaffolds for HIV-1 Immunogens - Methods and compositions are provided which employ chimeric polypeptides having at least one heterologous epitope for a human immunodeficiency virus type 1 (HIV-1) neutralizing antibody. These chimeric polypeptides behave as molecular scaffolds which are capable of presenting the various heterologous HIV-1 epitopes. The invention demonstrates that a heterologous epitope recognized by the HIV-1 neutralizing antibody can be more fully exposed to neutralizing antibodies when presented within the backbone of the chimeric polypeptide than when the epitope is presented within the context of an HIV-1 backbone. Polynucleotides encoding these chimeric polypeptides are also provided. Immunogenic compositions are provided which comprise a chimeric polypeptide having at least one heterologous epitope that interacts with an HIV-1 neutralizing antibody. Immuno genie compositions comprising chimeric polynucleotides encoding the chimeric polypeptides of the invention are also provided. Vaccines comprising such immunogenic compositions are also provided. Further provided are methods which employ the immunogenic compositions of the invention. Such methods include, for example, methods for eliciting an immune response in a subject, methods for generating antibodies specific for the chimeric polypeptide or the chimeric polypeptide, and methods for inhibiting or preventing infection by HIV-1 in a subject. | 06-25-2009 |